The following compounds were purchased from Sigma Aldrich (St. Louis, MO): citric acid (anhydrous, ≥ 99.5%), sodium hydroxide (anhydrous, ≥ 98%), n-octanol (anhydrous, ≥ 99%), porcine hematin, chloroquine diphosphate (≥ 98%), quinine (anhydrous, ≥ 98.0%), pyronaridine tetraphosphate (≥ 95%), amodiaquine dihydrochloride dihydrate, mefloquine hydrochloride (≥ 98%), and artemisinin (98%). All reagents were used as received. Deionized (DI) water was produced by a Millipore reverse osmosision exchange system (RiOs-8 Proguard 2 -MilliQ Q-guard).
Hematin and the tested antimalarial drugs were dissolved in CBSO. The solutions were filtered through a 0.22 polyvinylidene fluoride (PVDF) filter and the solute concentrations were determined by UVvis spectrophotometry. For hematin, we used extinction coefficient εΗ = 3.1 ± 0.3 cm -1 mM -1 determined as described in Ketchum, et al. (1) . For this study we used six drugs (quinine, QN; chloroquine, CQ; pyronaridine, PY; amodiaquine, AQ; mefloquine, MQ; and artemisinin; ART). The extinction coefficients of the tested drugs were determined analogously and were εCQ = 7.5 ± 0.2 cm -1 mM -1 at λ = 331 nm for chloroquine, εQN = 5.12 ± 0.02 cm -1 mM -1 at λ = 331 nm for quinine, εPY = 31.3 ± 0.8 cm -1 mM -1 at λ = 279 nm for pyronaridine, εAQ = 13.2 ± 0.2 cm -1 mM -1 at λ = 346 nm for amodiaquine, and εMQ = 2.712 ± 0.007 cm -1 mM -1 at λ = 315 nm from mefloquine. Since artemisinin absorbance in the tested UV -Vis range is not detectable, the concentration of artemisinin was determined gravimetrically from the weight of the dissolved substance assuming a pure drug reagent.
Growth of hematin crystals. Hematin crystals were grown from supersaturated hematin solutions in CBSO. Full details on the growth of large hematin crystals and their attachment to substrates suitable for in situ atomic force microscopy (AFM) imaging can be found in Olafson, et al. (2, 3) . All crystal synthesis and AFM experiments used freshly prepared CBSO solutions.
AFM imaging.
We employed a multimode atomic force microscope (Nanoscope IV) from Digital Instruments (Santa Barbara, CA) for all AFM experiments. AFM images were collected in tapping mode using Olympus TR800PSA probes (Silicon nitride probe, Cr/Au coated 5/30, 0.15 N/m spring constant) with tapping frequency 32 kHz. Image sizes ranged from 5 nm to 20 µm. Scan rates were between 1 and 2.52 s -1 . Height, amplitude, and phase imaging modes were employed. The captured images contained 256 scan lines at angles depending on the orientation of the monitored crystal(2, 3).
We processed height, amplitude, and phase images by flattening or plane fitting. Select images with sizes below 1 µm were processed with a 2D fast Fourier transform (FFT) filter to remove periodic noise. No lowpass or median filters were applied to any AFM images.
The temperature of the growth solution in the AFM fluid cell during in situ crystal growth monitoring was measured with a copper-constantan thermocouple connected to a temperature controller (SE5010, Marlow Industries Inc.). The thermocouple was calibrated using a crushed ice/DI water bath. The bath was allowed to equilibrate for 30 minutes and equilibration was verified at several locations with an accurate (±0.1°C) mercury thermometer. The thermocouple tip was secured to the thermometer. The set point of the controller was adjusted to read 0.0 ± 0.1°C. The thermocouple was embedded in a brass disk positioned under the AFM sample. The liquid cell was sealed with a silicon O-ring and loaded with CBSO. To replicate the experimental conditions, we continuously imaged for 3 hours a 2 × 2 µm 2 area at a scanning rate 2.52 s -1 . The temperature in the fluid cell reached a steady value of 27.8 ± 0.1°C within 15 min of imaging (2) . This value was higher than room temperature (ca. 22°C) owing to heating by the AFM scanner and laser.
In situ monitoring of the crystal surface evolution. Hematin crystals (ca. 20 µm in length) were grown on glass slides, which were mounted on AFM sample disks (Ted Pella Inc.). The samples were placed in the AFM scanner. We loaded the AFM fluid cell with a hematin solution in CBSO with concentration ca. 0.28 mM using 1 mL disposable polypropylene syringes, which are tolerant of the organic solvent. Crystallization solutions were prepared less than two hours in advance. After loading, this solution was allowed to thermally equilibrate for 15 -30 minutes. From the first AFM images, we identified the crystal edges in order to determine the crystallographic directions on the upward-facing (100) crystallographic face. Drugs were dissolved at known concentrations in a supersaturated hematin solution in CBSO and introduced to the AFM cell within 10 minutes of preparation. The system was again allowed to thermally equilibrate. To monitor surface evolution in the presence of antimalarials, AFM images were collected for ten or more hours. Drug-containing solutions were always introduced into the fluid cell after crystals were allowed to grow in pure solutions.
We collected numerous images, first in the absence of drugs and then in their presence, to determine the velocity of growth steps v and the rate of two-dimensional nucleation of new crystal layers J2D. To determine v, we monitored the displacements of 5 -12 individual steps. Only single steps, which exhibit a measured step height of 1.17 ± 0.07 nm, were considered. Different areas along a step were also monitored. Between 20 and 50 measurements were taken for each v data point, and we report the average. In most cases, the standard deviation of the sample was less than 10%, thus error bars were omitted in the plots. To determine J2D, we counted the number of new islands that appeared on the surface between two successive images. We monitored the evolution of each island in subsequent images and eliminated those that dissolve. This number was scaled with the imaged area and the time interval between images to yield J2D (nm -2 s -1
). These measurement were performed on six to 10 crystals growing in independently prepared solutions. The measurements were highly reproducible between the individual crystals.
Drug effects on bulk hematin crystallization. The antimalarial drugs were dissolved in CBSO, filtered through a 0.2 µm PVDF filter, and their concentration was determined spectrophotometrically. The drugs were added to a hematin stock solution to achieve final drug concentrations in the range from 1 to 20 µM, while maintaining a constant hematin concentration (cH = 0.24 mM). A microscope slide was placed in the crystallization container in contact with this supersaturated solution. The crystallization container was capped and placed in an incubator at 23°C with minimal exposure to light. Crystallization proceeded for 16 days. The microscope slides were rinsed with DI water and dried with pure ethanol. For SEM imaging, the slides and the crystal attached to them were coated with 15 nm gold.
All crystallization runs were done in triplicate. First, the crystal dimensions, used to evaluate the effect of a chosen drug concentration on the growth rate, were averaged within each run. The variations in the crystal sizes due to the presence of drugs were independently evaluated from the average sizes and were consistent between the runs. The crystal dimensions, plotted in Fig Fig. 5C reveals that the concentrations of QN and CQ that lead to a significant reduction of [H] are more than an order of magnitude higher than those that lead to complete growth cessation in Fig. 2 B and C. On the other hand, the AQ and MQ concentrations that induce significant inhibition of the step velocity in Fig. 3C are of the same order, albeit lower, than those required to lower [H] below the solubility ce. We used the scaling of v and cD depicted in Fig. 3D as evidence for kink blocking as the mechanism of action of these two drugs. To establish if the reduction of the concentration of free hematin due to sequestration in a drug-hematin complex affects this scaling, we substitute cH, which accounts for liganded and unliganded hematin, with [H], which accounts for only the unliganded hematin.
In the absence of drugs [H] = cH and the step velocity is(3)
where β is the step kinetic coefficient and Ω is the hematin molecular volume in the crystal. If we assume that the drug -hematin complex is not a growth inhibitor, the only action of a drug would be to lower [H] . In this case, v0 would decrease to
According to Eq. If, in addition to lowering cH, the drugs adsorb on kinks via a Langmuir-type law and block the incorporation of hematin, the relation between v and he drug concentration cD is modified. We follow the line of thought highlighted in the main text and obtain S8 ). These plots reveal that the data follow the predicted linear scaling of
Complexation of hematin with antimalarial drugs. Hematin solutions with initial volume V0 = 10 mL and cH = 0.3 and 0.03 mM were titrated with QN, CQ, PY, AQ, MQ, or ART by adding 0.25 mL aliquots of a solution of the tested drug in CBSO. This addition was repeated up to 30 times. At each titration step, a 0.5 mL sample of the drug -hematin mixture was decanted and a UV -Vis spectrum was collected. To test the reproducibility of the spectroscopic titration, each experiment was initially carried out with a coarser step requiring about 10 additions to reach saturation. After two 10-step titrations produced similar results, we titrated with smaller aliquot and reached saturation after 30 steps. The dependencies in Fig. 5B represent the results of 30 step titrations that overlap with two 10-step runs.
The spectra of hematin in the presence of drugs were similar to those in pure hematin solutions (Fig. S9) . They exhibit two peaks at 400 and 594 nm. The height of both peaks decreased upon addition of all drug-containing solutions. Observed changes in the absorbance upon titration may be associated with three phenomena: dilution of the hematin concentration by the newly added solution volume Vx, decrease of the concentration of free hematin due to complexation with the added drug, and the formation of drughematin complexes that absorb in the same wavelength range. To account for the solution dilution, we correct the recorded absorbance Ax to account for the increased solution volume from V0 to V0 + Vx
where cH,0 is the hematin concentration prior to drug addition and cH,T is the analytical concentration of hematin, including the amounts present as drug -hematin complexes, after drug addition; , = ,0 0 ( 0 + ) −1 . The correction of the spectra of the titration with CQ from Ax to Acorr is illustrated in Fig. S9 . The corrected spectra at several concentrations of QN, CQ, AQ, and MQ are displayed in Fig. 4A .
After accounting for dilution, the height of the peaks at 400 and 594 nm were independent of the concentrations of added PY (up to 17 µM, Fig. S10 ) and ART (up to 40 µM, Fig. S11 ). The drugs QN, CQ, AQ, and MQ do not absorb light at 594 nm (Fig. 4A) . In contrast, AQ exhibits weak absorbance at 400 nm. Hence, we chose to monitor changes in the absorbance at 594 nm as a function of the total drug concentration to characterize the drug -hematin complexation equilibrium. The choice of this wavelength offers an additional advantage. The weaker absorbance at 594 nm allowed us to use titration data with cH,0 = 0.3 mM, close to the hematin concentrations tested in our experiments (Figs. 1 -3) . Titrations of solutions with cH,0 = 0.03 mM containing QN, CQ or MQ,, in which drug -hematin complexes were characterized from the variation of the 400 nm peak, revealed binding mechanisms and respective equilibrium constants similar to those at cH,0 = 0.3 mM and 594 nm.
As an indicator of drug-hematin binding, we use the dependence on the total drug concentration cD of the ratio of Acorr at 594 nm to the absorbance of the pure hematin solution A0 at the same wavelength
where l = 1 cm is the optical path length. Combining Eqs. (4) and (5) yields
We fit the experimental Acorr(cD)/A0 dependencies for each drug to predictions of four models of drug -hematin complexation. We chose the best fit from the minimal mean squared deviation between the experimental Acorr(cD)/A0 data and corresponding model fits.
Model of a 1:1 drug:hematin complex.
The binding equilibrium and the respective equilibrium constant K are
Where [HD].
[H], and [D] are the equilibrium concentrations of the complex, unliganded hematin, and free drug, respectively. Using the hematin and drug mass balance relations for the known cH,T and cD
for each value of K we calculate the concentration of each species. Since the tested drugs do not absorb at the chosen wavelength of 594 nm, the measured absorbance Ax is
Substituting Eq. (9) in Eq. (6), we obtain
where εHD is the extinction coefficient of the HD complex.
We fit the relation in Eq. (10) to the data on the Acorr(cD)/A0 ratio with two adjustable parameters:
K and εHD. The starting values for the optimization of K were chosen between 0.001 and 1000, whereas the starting value for εHD was 0.7εH.
Model of a 1:2 drug:hematin complex.
The binding equilibrium and the respective constant are
The mass balance relations for known values of cH,T and cD are
The measured absorbance Ax and its ratio to the absorbance in pure hematin solution Acorr/A0 are
Analogously to the 1:1 drug: hematin model, we fit the relation in Eq. (14) to the data on the Acorr(cD)/A0 ratio with two adjustable parameters: K and εHD.
Two-step model of a 1:2 drug:hematin complex:
Here we consider a two-step process for the formation of a 1:2 drug:hematin complex, H2D. The binding equilibria and the respective constants are 
(20)
For Ax and Acorr/A0 we obtain
We optimized the fit of Eq. (22) to Acorr(cD)/A0 data as with the previous model.
Model fits were performed by minimizing the mean squared deviation between Eqs. (10), (14), (18), and (22) and experimental Acorr/A0 data obtained at 594 nm for each concentration of QN, CQ, AQ, and MQ. The measured Acorr/A0 ratios for QN, CQ, AQ, and MQ are plotted with the corresponding bestfit dependencies for each model in Figs. S12, S13, S14, and S15, respectively. The best-fit values of the corresponding binding constants and extinction coefficients are summarized in Table S1 . The last column in that table lists the value of the minimal mean squared deviation of the model curve from the experimental data. This deviation is lowest for the stepwise 2:1 drug:hematin complexation for QN. For CQ, AQ, and MQ, the lowest deviation results from the concerted formation of a 2:1 complex. The converging values of the binding constants and extinction coefficients for the best-fit model did not depend on the starting guesses of the optimization. In contrast, within models that provided poor fits, the final values of the binding constant varied depending on the starting value. The plots in Figs. S12 -S15 demonstrate that these models adequately describe the modification of the hematin absorbance in the presence of each of the four drugs.
We use the values of the binding constants K, K1 and K2 emerging from the best-fit model for each drug and the mass balances in Eqs. (8), (12), (16) 
